MetaCap

Henry Schein (HSIC) vs Natera (NTRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Natera (NTRA) has outperformed Henry Schein (HSIC) over the past year, gaining 18.5% versus a gain of 13.8%. Over five years, NTRA leads with a +188.8% price change compared with +13.4% for HSIC. Natera is the larger company by market cap ($39.64 billion vs $9.23 billion), about 4.3 times the size.

Henry Schein converts more of its revenue into profit, with a net margin of 3.0% versus -9.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HSIC+13.79%NTRA+18.54%
+95%+34%-26%
Nov 21, 20251 yearNov 20, 2026
HSIC+9.69%NTRA+164.97%
+320%+117%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HSIC versus NTRA key metrics
MetricHSICNTRA
Share price$83.52$273.40
Market cap$9.23B$39.64B
1-day change-1.51%-5.70%
YTD return+10.51%+19.34%
1-year return+13.79%+18.54%
5-year return+13.42%+188.82%
P/E ratio (TTM)22.88—
Forward P/E13.91—
EPS (TTM)$3.65$-1.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.18B$2.31B
Revenue growth (YoY)+4.03%+35.90%
Net income (latest FY)$398.00M$-208.16M
Gross margin31.14%—
Operating margin4.95%-13.44%
Net margin3.02%-9.03%
52-week high$92.18$437.41
52-week low$68.70$181.00
Distance from 52-week high-9.39%-37.50%
Analyst consensusbuystrong_buy
Avg. price target upside+15.98%+50.06%
Average volume1.33M1.77M
Shares outstanding110.54M145.00M
Employees25,0006,135
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Natera is about 4.3 times larger than Henry Schein by market value ($39.64B vs $9.23B).
  • Henry Schein is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -9.0 cents for Natera.
  • Natera grew revenue faster in its latest fiscal year (+35.90% vs +4.03%).

About Henry Schein

HSIC stock →

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.

Health Care · Medical Specialities · 25,000 employees

About Natera

NTRA stock →

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.

Health Care · Medical Specialities · 6,135 employees

HSIC vs NTRA FAQ

Which is bigger, Henry Schein or Natera?

Natera (NTRA) is larger, with a market capitalization of $39.64B compared with $9.23B for Henry Schein (HSIC).

Which stock has performed better over the past year, HSIC or NTRA?

NTRA returned +18.54% over the past 12 months, compared with +13.79% for HSIC (price return, excluding dividends). Past performance does not predict future results.

Are Henry Schein and Natera in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons